6275 Nancy Ridge Drive, Suite 100
3 articles with QPex Biopharma
Qpex Biopharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of innovative anti-infective therapies, announced today that it has initiated a Phase 1 clinical study of QPX7728, its novel ultra-broad-spectrum beta-lactamase inhibitor.
BioSpace is proud to present its NextGen Bio “Class of 2020,” a list of up-and-coming life science companies in North America that launched no earlier than mid-2018.
Qpex Biopharma Announces Exercise of $20 Million Option by BARDA under its Other Transaction Authority (OTA) Agreement to Advance Multiple Products into Clinical Studies
Qpex Biopharma, Inc., a biopharmaceutical company dedicated to the discovery and development of innovative anti-infective therapies, today announced that the Biomedical Advanced Research and Development Authority (BARDA) has exercised its first agreement option, which will support advancing multiple programs into clinical studies.